Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Sponsor
Seoul National University Hospital
Study ID
NCT02433795
Phase
PHASE2
Status
Completed

Conditions

  • Marginal Zone B-cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bendamustine plus rituximab — DRUG
    Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle

Study Details

This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).

Key Dates

Start date
May 31, 2015
Status verified
Sep 2021
Primary completion
Oct 31, 2019
Completion
Oct 31, 2019

Study Design

Enrollment
27 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bendamustine plus rituximab(BR)
    Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).

Primary Outcome Measure

Overall Response Rate [ Time Frame: Up to disease progression, more than 30.12 months ]

Related Studies